Natera CFO Michael Brophy sells $1.28 million of company stock By Investing.com

Michael Burkes Brophy, Chief Financial Officer of Natera, Inc. (), recently sold a total of 5,064 shares of company common stock, valued at $1,282,634, across several transactions. The sales occurred between July 27 and July 29, 2026, with prices ranging from $249.38 to $260.4908 per share. The transactions come as Natera shares trade at $253.82, reflecting an impressive 80% return over the past year. The genetic testing company now commands a market cap of $36.35 billion, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value, placing it among the most overvalued stocks in the market.

On July 27, Mr. Brophy sold 782 shares at a price of $260.4908 each. This transaction was executed to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units (RSUs) granted on January 26, 2024.

Further sales took place on July 28, where Mr. Brophy disposed of 1,241 shares at a weighted average price of $254.0705 per share, with individual sales ranging from $254.0696 to $254.3500. These shares were also sold to satisfy tax withholding obligations tied to RSUs granted on January 27, 2023. On the same day, an additional 1,008 shares were sold at a weighted average price of $253.7672, with individual sales ranging from $253.32 to $254.25, and 170 shares were sold at a weighted average price of $254.3338, with individual sales ranging from $254.32 to $254.3550. These latter sales on July 28, along with a sale of 1,863 shares on July 29 at $249.38 per share, were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Brophy on June 9, 2025, and modified on September 10, 2025.

Following these transactions, Mr. Brophy beneficially owns 52,432 shares of Natera common stock directly. For investors seeking deeper insights into Natera’s valuation and growth prospects, the company is covered in InvestingPro’s comprehensive Pro Research Report, one of 1,400+ US equities analyzed with expert intelligence and actionable metrics.

In other recent news, Natera Inc. has announced that its Signatera test has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR). This certification covers the Signatera platform, including the assay, specimen collection kit, and associated software, marking a significant regulatory achievement. Additionally, Natera published data in JAMA Oncology evaluating its Signatera molecular residual disease test in patients with resected colorectal liver metastases, showing the test’s potential in predicting chemotherapy benefits. In partnership news, Natera has teamed up with Aveta Biomics for a global Phase 3 clinical trial to evaluate APG-157 in patients with head and neck squamous cell carcinoma, utilizing the Signatera test to assess treatment response.

Moreover, Bernstein SocGen Group resumed coverage on Natera with an outperform rating, highlighting the company’s catalyst path to increased volumes and reimbursement in minimal residual disease testing. Japan is expected to be a significant volume driver, with PMDA reimbursement in the second quarter and a commercial launch anticipated before the end of the year. In the broader life science sector, TD Cowen released short interest data, noting significant increases for companies including Natera, MDxHealth, NeoGenomics, Bruker Corporation, and Illumina. These developments reflect ongoing activities and strategic movements within the industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.